Scarica l'app Stockscreener
1.47
2.80%
0.04
Dopo l'orario di chiusura:
1.43
-0.04
-2.72%
Inmed Pharmaceuticals Inc Borsa (INM) Ultime notizie
InMed Pharmaceuticals (INM) investor reports 4.2% beneficial stake in 137,634 shares - Stock Titan
Inmed Pharmaceuticals Stock Price Forecast. Should You Buy INM? - StockInvest.us
InMed Pharmaceuticals (INM) Rises 3.55% to $1.46 as Buyers Defend Key SupportMA Crossover - dars.gov.et
InMed Pharmaceuticals Inc (INM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InMed Pharmaceuticals Inc (INM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InMed Pharmaceuticals Inc (INM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InMed Pharmaceuticals Inc (INM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InMed Pharmaceuticals Inc (INM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InMed Pharmaceuticals Inc (INM) Institutional Confidence - TradingKey
INM|InMed Pharmaceuticals Inc|Price:1.580|Chg%:-0.130 - TradingKey
TradingKey - TradingKey
INM|InMed Pharmaceuticals Inc|Price:1.670|Chg%:-0.040 - TradingKey
InMed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:INM - TradingView
InMed Pharmaceuticals Inc (INM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ADAR1 Capital Management, LLC Acquires Additional Shares in InMed Pharmaceuticals Inc - GuruFocus
Mentari merger financing reshapes InMed Pharmaceuticals’ future - The Globe and Mail
Mentari Therapeutics Raises $200 Million for Migraine Prevention Pipeline Ahead of InMed Merger - Minichart
InMed Pharmaceuticals (INM) plans Mentari merger with $490M financings - Stock Titan
InMed to Merge with Mentari as Mentari Secures $200M Pre-Closing Financing - TradingView
InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline - Benzinga
INM Stock Whipsaws As InMed Refines Mentari Merger Terms - StocksToTrade
InMed Pharmaceuticals (NASDAQ:INM) climbs after $200 million Mentari infusion strengthens merger funding calculations - TechStock²
INM Stock Jumps As Traders Digest Amended Mentari Merger - StocksToTrade
INM Stock Jumps As Amended Mentari Merger Takes Shape - timothysykes.com
Morning Market Movers: INM, INLF, SXTC, ADVB See Big Swings - RTTNews
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline - PR Newswire
InMed Pharmaceuticals Inc (NASDAQ: INM) Share Price, INM Stock News, INM Share Price & Updates - Kalkine
InMed (NASDAQ: INM) outlines Mentari merger structure and names new CEO - Stock Titan
InMed Pharmaceuticals (INM) Gains 1.3% as Stock Approaches Key Resistance LevelForce Index - dars.gov.et
ADAR1 Capital acquires 1,000 InMed common shares worth $1,555 - Bitget
InMed Pharmaceuticals (INM) holder buys 1,000 common shares via ADAR1 - Stock Titan
Vivo Opportunity reports USD 32,319 purchase of InMed common shares - Bitget
Vivo Opportunity funds add 20,546 InMed Pharmaceuticals (INM) shares - Stock Titan
InMed Pharmaceuticals(INM) Stock Options Chain | Quotes & News - Moomoo
InMed Pharmaceuticals Company Profile & Introduction - Moomoo
InMed Pharmaceuticals and Mentari Therapeutics Amend Merger Agreement and File Registration Statement for Migraine Therapy Deal 1 – Minichart - Minichart
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
InMed amends merger terms, advances Mentari transition - TipRanks
InMed Pharmaceuticals (Nasdaq: INM) refines structure of planned Mentari merger - Stock Titan
InMed Pharmaceuticals Updates Mentari Merger Terms, Adding PIPE Option and Confirming Tax Reorganization - TradingView
InMed Pharmaceuticals (NASDAQ: INM) clarifies Mentari merger structure and targets Q4 2026 closing - Stock Titan
Enterprise value to EBIT forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
InMed Pharmaceuticals Amends Deal With Mentari Therapeutics - Moomoo
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-NIMU, INM, OLN, and HUN - The Malaysian Reserve
InMed Pharmaceuticals (INM) Moves Forward with Merger Agreement Amendments - GuruFocus
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 - TMX Newsfile
InMed Pharmaceuticals (INM) Stages 7% Advance: Testing Key Resistance LevelPut Dominated - DonanımHaber
InMed Pharmaceuticals และ Mentari Therapeutics ประกาศแก้ไขข้อตกลงการควบรวมกิจการ พร้อมยื่นแบบแสดงรายการข้อมูลการจดทะเบียน (Registration Statement) ตามแบบ Form S-4 - Moomoo
InMed Pharmaceuticals (INM) Slips 1.89% as Shares Test Key Support at $1.48Counter Trend Trade - dars.gov.et
INMInMed Pharmaceuticals Inc Forecast, Target Price - Finviz
Vivo Opportunity increases InMed (INM) stake with open-market share buys - Stock Titan
InMed (INM) to merge with Mentari after $290M financing; Exchange ~2.0606 - Stock Titan
InMed Pharmaceuticals Slides Slightly as INM Tests Key Support LevelSupport Level Bounce - dars.gov.et
InMed Pharmaceuticals (INM) Q3 2025 Earnings: Continued R&D Progress Amid No RevenueEnergy Earnings Report - DonanımHaber
Price to sales forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Price to earnings forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Enterprise value to revenue forward of InMed Pharmaceuticals Inc. – NASDAQ:INM - TradingView
Penny stock InMed Pharmaceuticals merger deal targets migraine pipeline - MSN
InMed Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:INM) - TradingView
0.79%
5.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):